If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 21 - 30 of 271
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors
Objective
A Dose-Escalation Study of XL092 in Subjects with Unresectable Advanced or Metastatic Solid Tumors
Protocol No
EXELIXIS-XL092-002
A Multicenter, Randomized, Open-Label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab Relative to Apixaban on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients with Cancer Associated VTE
Objective
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE (ASTER)
Protocol No
ANTHOS-ANT-007
Categories
Cancer,
Eye/Orbital Cancers,
Skin Cancers,
Cervix,
Lip, Oral Cavity and Pharynx,
Sarcoma,
Other Gastrointestinal,
Other Blood Related,
Pancreas/Liver,
Uterine,
Other Respiratory,
Gynecologic Cancers,
Brain and Spine Cancers,
Bladder,
Lung,
Head and Neck Cancers,
Leukemia,
Prostate,
Esophagus,
Thoracic Cancers,
Colorectal,
Hematologic/Blood Related Cancers,
Gastrointestinal Cancers,
Kidney,
Endocrine Cancers,
Prostate and Urologic Cancers,
Multiple Myeloma,
Breast Cancers
A Randomized Phase II Study Comparing Inotuzumab Plus Chemotherapy Versus Standard Chemotherapy in Older Adults with Philadelphia-Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
Objective
This study is being done to answer the following question: Can we improve the chance of your leukemia going away (remission) and lower the chance of your leukemia coming back (relapsing) by adding an investigational drug called inotuzumab ozogamicin (hereafter, inotuzumab) to lower doses of the usual chemotherapy for acute lymphoblastic leukemia?
We are doing this study because we want to find out if this approach is better or worse than the
usual approach for your acute lymphoblastic leukemia. The usual approach is defined as care
most people get for acute lymphoblastic leukemia.
We are doing this study because we want to find out if this approach is better or worse than the
usual approach for your acute lymphoblastic leukemia. The usual approach is defined as care
most people get for acute lymphoblastic leukemia.
Protocol No
ALLIANCE-A042001
Categories
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients with Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Ind
Objective
A Phase 1/2, Study of Gilteritinib, Venetoclax and Azacitidine in Patients with AML
Protocol No
ASTELLAS-2215-CL-0203
Categories
Phase II Randomized, Prospective Trial of Lutetium Lu 177 Dotatate PRRT Versus Capecitabine and Temozolomide in Well-Differentiated Pancreatic Neuroendocrine Tumors
Objective
Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors
Protocol No
ALLIANCE-A022001-PNETS
Categories
A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
Objective
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
Protocol No
ALLIANCE-A022101-ERASUR
Categories
A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (RadiCal)
Objective
Cabozantinib + New Anti-cancer Drug Radium-223 Dichloride for Advanced RCC that's Spread to the Bone
Protocol No
ALLIANCE-A031801-RADICAL
Categories
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
Objective
Collection of research data and samples from patients who experience immunotherapy side effects
Protocol No
ALLIANCE-A151804
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Objective
Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Protocol No
ALLIANCE-ALCHEMIST-A151216
Categories
A Multi-site, Open-label, Phase II, Randomized, Controlled Trial to Compare the Efficacy of RO7198457 Versus Watchful Waiting in Resected, Stage II (High Risk) and Stage III Colorectal Cancer Patients Who Are ctDNA Positive Following Resection
Objective
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
Protocol No
BIONTECH-BNT-122-01
Categories